Posts
- Category: Articles (continued)
- The Faces of Huntington's Disease - July 2012
- The Faces of Huntington's Disease The Huntington's Disease Project Magazine!
- The first dose is hope: moving towards treatments for Huntington’s disease
- The Huntington Study Group announces first-HD study
- The Huntington's Disease Project - 2012 Trailer (Italian Version)
- The Huntington’s Disease Project
- The Huntington’s Disease Project
- The incredible lightness – and responsibility – of exiting the Huntington’s closet
- The Lancet Neurology publishes Prana’s Huntington’s Disease Trial
- The Lancet Neurology: Scientists Identify Early Predictors of Huntington’s Disease Progression Wake Forest Neurologist Applauds Research
- The messenger in Huntingon's disease
- The Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at the scientific conference “American Academy of Neurology – AAN” in Philadelphia, PA, on May 6 2019
- The Potential for New Therapeutic Approaches: Global Research Collaboration Examines Multiple Pathways of Neuroprotection in Huntington Disease
- The precious participation of the Huntington’s disease community in the quest for treatments: a report on the 2015 HD Therapeutics Conference
- The UCL Huntington’s Disease Centre
- Thomson Reuters Partners with CHDI Foundation to Develop Systems Biology Tools for Huntington's Disease
- Thousands Join Lundbeck and the Hereditary Disease Foundation to Build Hope for Huntington’s Disease
- Toward a Salivary Biomarker for Huntington Disease
- Treating Huntington’s disease: making new neurons is not enough
- Treating MS Without Dangerous Drugs
- Treatments For Neurodegenerative Disorders - Global Forecast, Market Share, Size, Growth And Industry Analysis, 2012 - 2018
- Triplet Repeat Primed PCR Simplifies Testing for Huntington Disease
- TSRI Scientists Find Drug That Helps Huntington's Disease-Afflicted Mice-and Their Offspring
- Turning skin cells into brain cells
- Two Proteins Offer a “Clearer” Way to Treat Huntington’s Disease
- UBC scientists develop test to measure effectiveness of treatments for Huntington’s disease
- UC San Diego Health System Named Center of Excellence for Huntington’s Disease
- Uguale, ma diversa: la Malattia di Huntington Giovanile -
- Un voto, 100.000 aiuti concreti – Summer Edition
- UniQure
- uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntington’s Disease
- uniQure Announces FDA Orphan Drug Designation for AMT-130 in Huntington's disease
- uniQure licenses RNA interference technology to advance Huntington’s disease program
- uniQure Presents New Preclinical Data on AMT-130 at the CHDI’s 14th Annual Huntington’s Disease Therapeutics Conference
- uniQure Presents New Preclinical Data on AMT-130 in Huntington's Disease at CHDI's 12th Annual Huntington's Disease Therapeutics Conference
- uniQure Presents New Preclinical Data on AMT-130 in Huntington’s Disease at the ESGCT 25th Anniversary Congress in Berlin
- uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
- uniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130 for Huntington’s Disease
- Unmet Medical Needs Drive the Global Huntington’s Disease Therapeutics Market, According to New Report by Global Industry Analysts, Inc.
- Unraveling the mysteries of the mitochondria in Huntington’s disease – and getting fast, clear, and useful results from research studies
- Update on molecular therapies for Huntington’s disease
- Using exercise to reduce glutamate build-up in the brain
- Utah Chemists Use Nanopores to Detect DNA Damage
- Vaccinex Inc. Completes Enrollment of Cohort A in its SIGNAL Clinical Trial, a Randomized Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503 in Subjects at Risk for or with Early Signs of Huntington’s Disease
- Vaccinex Receives FDA Fast Track Designation for VX15 Antibody for the Treatment of Huntington’s Disease
- Vaccinex, Inc. Announces Preliminary Data from the SIGNAL Clinical Trial (Investigational Drug VX15/2503 as a Potential Treatment for Huntington’s Disease)
- Vaccinex, Inc. Receives Orphan Drug Designation from U.S. FDA for its Lead Antibody Product Candidate, VX15, as a Potential Treatment for Huntington’s Disease
- Voyager Therapeutics & Genzyme Announce Major Strategic Collaboration to Develop and Commercialize Novel AAV Gene Therapies for Patients with CNS Disorders
- Voyager Therapeutics Announces Preclinical Data for Huntington’s Disease and Amyotrophic Lateral Sclerosis Programs at the Congress of the European Society of Gene and Cell Therapy
- Voyager Therapeutics Selects Lead Clinical Candidate for Huntington’s Disease
Plugin by dagondesign.com
